Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041) (C-PHONE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00211601
First received: September 13, 2005
Last updated: May 2, 2014
Last verified: May 2014

September 13, 2005
May 2, 2014
August 2004
Not Provided
CINV at the delayed phase during cycle 2
Same as current
Complete list of historical versions of study NCT00211601 on ClinicalTrials.gov Archive Site
Treatment for CINV
Same as current
Not Provided
Not Provided
 
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis

The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Chemotherapy Induced Nausea and Vomiting
Behavioral: Disease Management Assessment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1500
December 2005
Not Provided

Inclusion Criteria:

  • Highly or moderately emetogenic chemotherapy planned for at least 2 cycles

Exclusion Criteria:

  • Concurrent other anti-cancer therapy (e.g. radiation, hormone, etc.); vomiting during the 24 hours prior to first chemotherapy cycle; having a disease/condition or taking medication that may cause emesis
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00211601
0000-041, 041, 2005_072
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP